Nektar Therapeutics (NKTR) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$1.23
- EPS estimate
- −$1.97
- EPS surprise
- +37.60%
- Revenue surprise
- −2.82%
- Revenue
- $10.1M
- Revenue estimate
- $10.4M
- Reported
- Aug 13, 2026
Nektar Therapeutics reported Q2 2026 results on August 13, 2026. The company posted a loss of $1.23 per share, narrower than the $1.97 loss analysts expected, a 37.60% beat. Revenue was $10.1 million, slightly below the $10.4 million estimate. In Q2 2025 the loss was $2.95 per share and revenue was $11.2 million, so revenue fell 9.8% year over year.
Nektar posted a loss in 19 of the 20 quarters in the table. The only profit was $0.45 per share in Q4 2024. Annual losses per share were $29.55 in 2022, $21.90 in 2023, $8.85 in 2024 and $10.20 in 2025. Revenue fell from $98.4 million in 2024 to $55.3 million in 2025, and quarterly revenue has stayed between $10 million and $12 million in four of the last five quarters. The first half of 2026 lost $3.05 per share, against $6.55 a year earlier. The loss came in narrower than expected in 13 of the 20 quarters, including Q2 2026.
Q3 results came out between November 3 and November 7 in each of the past five years. That points to early November 2026 for the next report, which will show whether the smaller first-half losses continue.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 13, 2026 | −$1.97 | −$1.23 | +37.60% | $10.1M | SEC |
| Q1 2026 | May 7, 2026 | −$1.58 | −$1.82 | −15.02% | $10.9M | SEC |
| Q4 2025 | Mar 12, 2026 | −$2.47 | −$1.78 | +28.05% | $21.8M | SEC |
| Q3 2025 | Nov 6, 2025 | −$2.68 | −$1.87 | +30.35% | $11.8M | SEC |
| Q2 2025 | Aug 7, 2025 | −$3.03 | −$2.95 | +2.56% | $11.2M | SEC |
| Q1 2025 | May 8, 2025 | −$2.56 | −$3.60 | −40.39% | $10.5M | SEC |
| Q4 2024 | Mar 12, 2025 | −$2.03 | $0.45 | +122.12% | $29.2M | SEC |
| Q3 2024 | Nov 7, 2024 | −$2.99 | −$2.70 | +9.55% | $24.1M | SEC |
| Q2 2024 | Aug 8, 2024 | −$2.78 | −$3.75 | −35.14% | $23.5M | SEC |
| Q1 2024 | May 9, 2024 | −$2.85 | −$2.85 | +0.00% | $21.6M | SEC |
| Q4 2023 | Mar 4, 2024 | −$3.16 | −$3.30 | −4.54% | $23.9M | SEC |
| Q3 2023 | Nov 7, 2023 | −$2.97 | −$3.60 | −21.02% | $24.1M | SEC |
| Q2 2023 | Aug 8, 2023 | −$4.22 | −$4.05 | +4.08% | $20.5M | SEC |
| Q1 2023 | May 9, 2023 | −$3.72 | −$10.95 | −194.31% | $21.6M | SEC |
| Q4 2022 | Feb 28, 2023 | −$6.78 | −$4.80 | +29.19% | $22.0M | SEC |
| Q3 2022 | Nov 3, 2022 | −$6.74 | −$4.65 | +30.96% | $23.6M | — |
| Q2 2022 | Aug 4, 2022 | −$14.55 | −$12.75 | +12.37% | $21.6M | — |
| Q1 2022 | May 5, 2022 | −$9.46 | −$7.35 | +22.33% | $24.8M | — |
| Q4 2021 | Feb 28, 2022 | −$12.05 | −$11.85 | +1.66% | $25.0M | — |
| Q3 2021 | Nov 4, 2021 | −$11.97 | −$10.50 | +12.28% | $24.9M | — |
Quarterly revenue
Frequently asked questions
When did Nektar Therapeutics (NKTR) last report earnings?
Nektar Therapeutics last reported on Aug 13, 2026, covering fiscal Q2 2026.
Did NKTR beat earnings estimates?
Yes. Nektar Therapeutics reported EPS of −$1.23 for Q2 2026 against a −$1.97 estimate — a 37.60% beat.
How much revenue did NKTR report last quarter?
Nektar Therapeutics reported $10.1M in revenue for Q2 2026, against a consensus estimate of $10.4M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.